Flex Pharma, Inc. (FLKS)
(Delayed Data from NSDQ)
$0.46 USD
-0.02 (-3.26%)
Updated May 3, 2019 03:59 PM ET
After-Market: $0.46 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$0.46 USD
-0.02 (-3.26%)
Updated May 3, 2019 03:59 PM ET
After-Market: $0.46 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Flex Pharma (FLKS) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Flex Pharma (FLKS) delivered earnings and revenue surprises of -28.21% and 23.00%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Flex Pharma Down on Workforce Reduction, Ends Phase II Study
by Zacks Equity Research
Flex Pharma (FLKS) announced that the company is ending the phase II studies for its pipeline candidate FLX-787 in two indications. The company also plans to lower its workforce by about 60%.